Loading...
XSWXRLF
Market cap64mUSD
Dec 23, Last price  
4.10CHF
1D
-5.75%
1Q
67.35%
Jan 2017
-65.83%
IPO
-99.68%
Name

Relief Therapeutics Holding SA

Chart & Performance

D1W1MN
XSWX:RLF chart
P/E
—
P/S
9.60
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
18.05%
Rev. gr., 5y
60.47%
Revenues
6m
-0.79%
14,827,18414,545,20013,740,340386,3820020,714,33219,490,181256,11715,0000567,000003,321,0006,081,0006,033,000
Net income
-98m
L+93.31%
-2,000,288-9,400,835-12,213,643-19,396,973-59,166,000-6,484,988000-16,834,000-2,887,000-436,000-7,460,000-7,828,000-34,705,000-50,790,000-98,181,000
CFO
-18m
L-26.95%
-3,730,900-9,554,639-3,316,076-16,443,609-10,243,841-4,645,876000-2,888,000-1,173,000-618,000-748,000-18,234,000-35,711,000-24,108,000-17,612,000
Earnings
Apr 28, 2025

Profile

Relief Therapeutics Holding AG, a biopharmaceutical company, provides patients with therapeutic relief from serious diseases with high unmet medical need in Switzerland, rest of Europe, North America, and internationally. The company focuses on clinical-stage programs based on molecules with a history of clinical use and either initial human activity or efficacy data or a strong scientific rationale. Its lead compound is RLF-100 (aviptadil), a synthetic human vasoactive intestinal peptide (VIP) with a multifaceted mode of action for respiratory indications, which is in Phase 3 clinical trials for treating COVID-19-induced acute respiratory distress syndrome and moderate to severe COVID-19 lung injury; in Phase 1 clinical trial for the treatment of patients with acute lung injury in other intensive care unit; and in Phase 2 clinical trial for the treatment of pulmonary sarcoidosis. The company is also developing ACER-001, a proprietary powder formulation of sodium phenylbutyrate, which has completed Phase 3 clinical trial for urea cycle disorders; and in Phase 1 clinical trial for the treatment of maple syrup urine disease. In addition, it is developing APR-TD011, a spray-formulated hypotonic acid-oxidizing solution, which is in Phase 2 clinical trial for treating epidermolysis bullosa. The company was founded in 2013 and is based in Geneva, Switzerland.
URL
https://relieftherapeutics.com/
IPO date
Sep 19, 2011
Employees
69
Domiciled in
CH
Incorporated in
CH

Valuation

Title
CHF in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
6,033
-0.79%
6,081
83.11%
3,321
 
Cost of revenue
22,677
41,555
36,946
Unusual Expense (Income)
NOPBT
(16,644)
(35,474)
(33,625)
NOPBT Margin
Operating Taxes
(13,503)
(3,526)
(820)
Tax Rate
NOPAT
(3,141)
(31,948)
(32,805)
Net income
(98,181)
93.31%
(50,790)
46.35%
(34,705)
343.34%
Dividends
Dividend yield
Proceeds from repurchase of equity
5,094
6,888
73,240
BB yield
Debt
Debt current
861
2,096
1,676
Long-term debt
4,705
2,248
2,588
Deferred revenue
2,232
2,192
Other long-term liabilities
7,792
9,681
22,263
Net debt
(8,990)
(7,875)
(31,839)
Cash flow
Cash from operating activities
(17,612)
(24,108)
(35,711)
CAPEX
(446)
(521)
(13,708)
Cash from investing activities
8,695
(8,017)
(30,269)
Cash from financing activities
4,050
6,417
67,689
FCF
(3,417)
(32,103)
(35,341)
Balance
Cash
14,556
19,237
44,761
Long term investments
(7,018)
(8,658)
Excess cash
14,254
11,915
35,937
Stockholders' equity
(155,951)
(58,163)
(22,992)
Invested Capital
218,927
217,258
230,563
ROIC
ROCE
EV
Common stock shares outstanding
11,752
10,570
8,983
Price
Market cap
EV
EBITDA
(13,326)
(31,614)
(31,589)
EV/EBITDA
Interest
330
196
268
Interest/NOPBT